4DMT’s 4D-150 gene drug for the intravitreal treatment of wet AMD received FDA Regenerative Medicine Advanced Therapy (RMAT) designation, the first RMAT designation for wet AMD
4D Molecular Therapeutics Inc. The designation follows interim Phase 1 PRISM clinical data for 4D-150 that demonstrated an encouraging safety, tolerability and clinical activity profile in patients with wet age-related …